Events

“The Biopharma Sustainability Roundtable and Investor Day are an incredibly good use of my time – providing an excellent opportunity to learn from peers, share best practices, understand trends and get re-energized for the important work we all do. I emerge with practical learnings that I can apply immediately and which I am eager to share with colleagues.”

Upcoming Events

Recent Events

November 5-6, 2024

2024 Biopharma Sustainability Conference

Hosted by Sanofi, Paris

November 7, 2024

2024 Biopharma Sustainability Investor Day

Hosted by Sanofi, Paris

September 3, 2024

BSRT Forum with RepRisk

RepRisk is one of the world’s leading data providers for ESG and Business Conduct, identifying and assessing material ESG risks for corporations based on purely external sources. RepRisk supports investment and financing decisions by some of the world’s largest banks, asset managers and sovereign wealth funds, and many well-known corporate Ratings, Award Schemes, and Index providers embed RepRisk data in their evaluations, including S&P Dow Jones Indices, Bloomberg, CDP, FTSE Russell, Corporate Knights, and Ethisphere. 
June 18, 2024

Regulatory and ESG Policy Outlook for Biopharma

Our 6th annual update with EcoFact on global Regulatory and ESG policy developments.  The online forum presented a deep dive into current and emerging ESG regulations that will affect our sector. Reporting requirements, due diligence regulations, climate transition planning, and nature-related risks were all part of the discussion, along with updates on emerging topics like the link between ESG and AI.

June 17, 2024

Biopharma Investor ESG Communications In-Person Workshop

A focused group of Biopharma sustainability leaders and Biopharma sector investors convened for a direct conversation about the sector’s highest priority ESG/Sustainability topics, sparked by initial group survey results.  The Workshop provided input towards our next public update of the Biopharma Investor ESG Communications Guidance.

June 5, 2024

Biopharma and Human Rights: The Right to Health

Harold Nusser, a seasoned healthcare executive with global experience in health equity and social business, opened our discussion about Biopharma and Human Rights with a focus on the right to health. Additional perspectives were shared by BSRT colleagues from Hikma, Organon, Pfizer, and Roche.

April 10, 2024

CSRD & Taxonomy Implementation

Jens Reissmann, Project Lead for CSRD at Bayer, shares their project strategy and experience with CSRD and Taxonomy Implementation.

February 6, 2024

Patient Engagement - Making the Connection with ESG

Zack Pemberton-Whiteley, Exec. Director, Global Patient Engagement at Novartis, explores Patient engagement (PE) as a key topic within the ESG landscape, and its connections to long-term success.

October 5, 2023

Biopharma Sustainability Investor Day 2023

Manhattan, NYC

October 3-4, 2023

Biopharma Sustainability Roundtable Annual Meeting 2023​

Hosted by Organon, Jersey City

June 13, 2023

BSRT Forum with EcoFact

Our 5th annual update with EcoFact on global regulatory and ESG policy developments and trends salient for the biopharma sector. The discussion focuses on topics where ESG policy and regulation is evolving rapidly and the changes will affect biopharma companies, directly or indirectly.

May 18, 2023

BSRT Forum with IFPW

International Federation of Pharmaceutical Wholesalers (IFPW) — A conversation about their new ESG Framework for Healthcare. In early 2023, IFPW launched its ESG Framework for Healthcare to help create global alignment and consistency across the pharmaceutical sector on how to effectively communicate and report the impact of environmental, social, and corporate governance initiatives that advance the supply chain.

December 15, 2022

A conversation with Bob Eccles on ESG

Bob Eccles, Visiting Professor of Management Practice, Saïd Business School, University of Oxford; Founding Chairman of SASB

Sep 29, 2022

Investor Day​

BSRT Conference 2022 
Host: Nasdaq Copenhagen

Sep 27-28, 2022​

Biopharma Sustainability Roundtable​

BSRT Conference 2022 
Host: Novo Nordisk, Copenhagen​

August 18, 2022

Impact Metrics

Dennis Ostwald, CEO of the WifOR Institute, and Sonja Haut, Head Impact Valuation at Novartis, take us on a deep dive into health from the perspective of its economic impact, how Novartis is implementing impact valuation, and what this approach could mean for the Biopharma sector.

July 6, 2022

Roundtable Forum

Jens Reissmann, Project Lead for EU Taxonomy Reporting at Bayer, shared insights and practical learnings from Bayer’s work on fulfilling these critical new reporting requirements, and put it into the wider context of embedding Sustainability/ESG in management accounting, and preparing for ‘still to come’ external disclosure requirements.

June 28, 2022

Roundtable Forum

ESG Standards and Regulatory Progress with ECOFACT, an update on global policy developments around ESG that will affect biopharma directly or indirectly in the near-term. Fourth in an ongoing series tailored for BSRT participants.

June 8, 2022

BSRT Forum

Health Outcomes Observatory (H2O) with Meni Styliadou, H2O Founder and Co-Leader, Distinguished Fellow of the Data Sciences Institute and VP of Government Affairs, Public Policy, and Sustainable Healthcare at Takeda

In conversation with Francesco Patalano, H2O Working Group Leader and Head of Pediatric and Patient Reported Outcomes Centers of Excellence at Novartis, and Madeleine Brady, H2O Communications (Moderator)

March 17, 2022

BSRT Forum

20+ Years of Sustainability Leadership – A conversation with Lars Rebien Sørensen

February 16, 2022

Biopharma Investor Workshop #4

Continuing the dialog between biopharma leaders and capital markets representatives on how to structure effective, efficient, and decision-useful communications about ESG strategy and performance.
February 14, 2022

Biopharma Sustainability — A Global Perspective

Towards a global perspective on Biopharma sustainability, hosted by the ESG Disclosure Study Group, Japan.